207_Combined course Presentations

Take Home Message (DLBCL)

 The development of tailored therapy according to the relapse risk is warranted, rather than uniform treatment of all early-stage DLCL (bulky disease, PET-oriented treatment)

 Therapeutic burden: R-CHOP x 3 cycles followed by 30 Gy IF-RT probably better than R-CHOP x 6 cycles (less toxic and probably higher survival rates)

 Consolidative RT is strongly recommended, even after 6 R-CHOP and in advanced stage DLBCL, for patients with bulky lesions or skeletal involvement